The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.

@article{Katlama2000TheRO,
  title={The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.},
  author={Christine Katlama and Bonaventura Clotet and Andreas Plettenberg and Josef Jost and Keikawus Arast{\'e}h and Enos Bernasconi and Vincent Jeantils and Amy G Cutrell and Chris Stone and Mounir Ait-Khaled and Scot E. Purdon},
  journal={AIDS},
  year={2000},
  volume={14 7},
  pages={781-9}
}
OBJECTIVE To compare the antiviral activity of abacavir (ABC) with stable background therapy (SBG) and SBG alone in antiretroviral therapy-experienced subjects as demonstrated by the proportion of subjects with plasma HIV-1 RNA < or = 400 copies/ml, plasma HIV-1 RNA and CD4 cell count profiles, and safety and tolerance of the two regimens over 16 weeks. DESIGN One-hundred and eighty-five HIV-1 infected adults, with CD4 cell counts > or = 100 x 10(6)/l and plasma HIV-1 RNA of 400-50,000 copies… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…